Abstract:Introduction: GBM is the most common primary malignancy of the CNS. Historically pre-clinical models have failed to predict response in humans, despite promising preclinical data. Moreover, current models seldom incorporate surgical resection and/or standard of care chemotherapy treatment. These models also commonly employ young animals exclusively, whose immune contexture differs from older patients. We therefore sought to establish an improved, orthotopic, preclinical GBM model, which better recapitulates patient response to standard-of-care and targeted treatments. Methods: NFpp10a-Luc2 GBM cells were orthotopically implanted into C57BL/6-mice (aged[>18months] and young[6-8weeks]) and weekly bioluminescence imaging performed to monitor tumor growth. Overall survival (OS) and tumor growth were assessed in response to (1) Surgical Resection, (2) Temozolomide (TMZ) (3) anti-PD1 (4) neoadjuvant anti-PD1 and (5) Regorafenib (REGO) therapy. Tissue collected post-mortem underwent bulk RNA sequencing followed by analysis via microenvironment cell population counter (MCP) and gene set enrichment (GSEA) to determine changes in the GBM-TME following treatment. Results: We demonstrated OS advantage in aged mice undergoing surgical resection (Resection:33.5 days vs Non-Resection: 18 days; p=0.0166) and observed age to be a significant prognostic factor (Young:62 days vs Aged: 22 days; p=0.0002). Subsequently, we observed that TMZ and anti-PD1 monotherapies had no impact on NFpp10-Luc2 growth (p=0.9001, p=0.7933) or survival (p=0.3035, p=0.6328). Neoadjuvant anti-PD1 treated mice demonstrated no significant survival advantage compared to IgG control (33 days vs 35 days; p=0.9429). Lastly, REGO treatment demonstrated a trend towards improved OS vs Vehicle (p=0.096). MCP analysis revealed both neoadjuvant anti-PD1 and REGO treatment induced influx of CD8+ T cells, B cells and monocytes into the TME, with neoadjuvant anti-PD1 associated with an upregulation of CXCR3 (p=0.0045). Conclusions: We have, for the first time, established and characterized response of the NFpp10a-C57BL/6 model to surgical resection, TMZ, anti-PD1 and REGO therapy in both young and aged mice. We have shown the model is markedly insensitive to intervention with chemotherapy and immune checkpoint therapy, mirroring what is seen clinically in patients. The model may therefore be employed in future pre-clinical studies to guide clinical trials in the setting of mesenchymal GBM. Citation Format: Kate Connor, Kieron White, James Clerkin, Kieron Sweeney, Liam Shiels, Thomas van Brussel, Ingrid Arijs, Diether Lambrechts, Gautam Shankar, Frederik de Smet, Stephen G. Maher, Laure Marignol, Patrick Dicker, Jochen Prehn, David O'Brien, Annette T. Byrne. Establishing a novel clinically relevant disease model of glioblastoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 1441.

Haploinsufficiency of Adenomatous Polyposis Coli Coupled with Kirsten Rat Sarcoma Viral Oncogene Homologue Activation and P53 Loss Provokes High-Grade Glioblastoma Formation in Mice

Tmod-35. Egfrviii Overexpression And Loss Of Mouse Specific Cdkn2A In Glial Cells Leads To Spontaneous Gliomagenesis In A Novel Mouse Model

A new method of identifying glioblastoma subtypes and creation of corresponding animal models

Rapid tumor recurrence in a novel murine GBM surgical model is associated with Akt/PD-L1/vimentin signaling

GENT-06. IN VIVO EXPRESSION OF MUTATED IDH1 (R132H) GENE IN A MOUSE MODEL OF YOUNG ADULT GLIOBLASTOMA HAS IMPACT IN MEDIAN SURVIVAL, DNA-REPAIR PATHWAYS, AUTOPHAGY AND OLIGODENDROCYTE DIFFERENTIATION

Abstract 1441: Establishing a novel clinically relevant disease model of glioblastoma

TMOD-18. DIRECT IN VIVO CRISPR SCREEN IDENTIFIES COOPERATING TUMOR SUPPRESSORS THAT DRIVE PROGRESSION OF IDH1-MUTANT LOW-GRADE GLIOMA TO AGGRESSIVE GLIOBLASTOMA

Tmod-31. Single-Cell Profiling And Characterization Of Patient-Derived Xenograft Glioblastoma Model In Humanized Mice

Tmod-01. Egfr Amplification Accompanies Adaptation To Mitogen-Induced Defective Mitosis In Pdgfa

Mouse models of pediatric high-grade gliomas with MYCN amplification reveal intratumoral heterogeneity and lineage signatures

Expression of Mutant p53 Proteins Implicates a Lineage Relationship between Neural Stem Cells and Malignant Astrocytic Glioma in a Murine Model

Dddr-39. Pi3 Kinase And Checkpoint Inhibition: A Potentially Novel Therapeutic Strategy For Glioblastoma (Gbm)

Loss of <i>p53</i> Concurrent with <i>RAS</i> and <i>TERT</i> Activation Induces Glioma Formation

A more efficient method for generating glioblastoma-multiforme model in mice using genome editing technology

Abstract C10: Neural Stem Cells and Lineage-Restricted Progenitors Can Initiate Malignant Astrocytoma Formation in Somatic Tumor Suppressor Mouse Models

MODL-14. IMAGING, HISTOLOGICAL AND MOLECULAR CHARACTERIZATION AND COMPARISON OF POST-ABLATION RECURRENT TUMOR WITH THE PRIMARY TUMOR IN A PRECLINICAL GLIOBLASTOMA MODEL

Mouse models of glioblastoma for the evaluation of novel therapeutic strategies

Translational Orthotopic Models of Glioblastoma Multiforme

A PDGFRα-driven mouse model of glioblastoma reveals a stathmin1-mediated mechanism of sensitivity to vinblastine

Loss of p53 Concurrent with RAS and TERT Activation Induces Glioma Formation

Murine Models of IDH-wild-type Glioblastoma Exhibit Spatial Segregation of Tumor Initiation and Manifestation During Evolution.